Evidence map›Paper›PMID 40052563›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Visual-somatosensory integration as a novel behavioral marker of amyloid pathology.

Jeannette R Mahoney, Emmeline Ayers, Joe Verghese

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Visual-somatosensory integration as a novel behavioral marker of amyloid pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jeannette R MahoneyDepartment of Neurology, Division of Cognitive and Sensorimotor Aging, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.ORCID 0000-0003-1079-787X
Emmeline AyersDepartment of Neurology, Division of Cognitive and Sensorimotor Aging, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
Joe VergheseDepartment of Neurology, Division of Cognitive and Sensorimotor Aging, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.

Funding

The biological underpinnings of Motoric Cognitive Risk syndrome: a multi-center studyR01AG057548 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI VERGHESE, JOE · 2020 to 2024
$8.0M
Visual-somatosensory integration as a novel marker of Alzheimer's diseaseR01AG075679 · NIA · STATE UNIVERSITY NEW YORK STONY BROOK · PI Jeannette R. Mahoney · 2022 to 2026
$3.7M
Biological and neural mechanisms of fallsR01AG044007 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI VERGHESE, JOE · 2013 to 2017
$3.5M
Central Control of Mobility in AgingR01AG036921 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HOLTZER, ROEE · 2011 to 2015
$3.3M
Neurobiological Substrates of Visual-Somatosensory Integration in AgingK01AG049813 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI MAHONEY, JEANNETTE R. · 2016 to 2021
$818k
NIA NIH HHS K01 AG049813NIA NIH HHS L30 AG043170NIA NIH HHS R01 AG036921NIA NIH HHS R01 AG044007NIA NIH HHS R01 AG057548NIA NIH HHS R01 AG075679NIH HHS K01AG049813NIH HHS R01AG036921NIH HHS R01AG044007NIH HHS R01AG057548NIH HHS R01AG057548-02S1NIH HHS R01AG075679Resnick Gerontology Center of the Albert Einstein College of Medicine
6 · The paper itself

Abstract

introductionThe ability to integrate information across sensory modalities is a vital aspect of everyday functioning and is linked to cognition. Increasing evidence suggests that Alzheimer's disease (AD) pathology manifests in sensory association areas before appearing in higher-order cognitive areas. We examined the role of visual-somatosensory integration (VSI) as a novel behavioral marker of AD-associated amyloid pathology.

methodsThis cross-sectional study included 243 adults (77 ± 6.5 years; 52% female) who completed the VSI test and AD biomarker assays. The magnitude of VSI was the independent variable and amyloid-beta probability scores (APS; PrecivityAD

resultsLinear regression revealed an inverse association between the magnitude of VSI and APS (β = -0.16; p ≤ 0.01). As cognitive impairment increased from normal to dementia, the magnitude of VSI decreased (p < 0.05). DISCUSSION: Findings provide support for VSI impairment as a new behavioral marker of AD-associated amyloid pathology. HIGHLIGHTS: Here we provide support for the magnitude of VSI as a novel behavioral marker of AD-associated amyloid pathology given its significant association with an established, accurate, and reliable biomarker of AD pathology. Adults with normal cognition maintained the highest magnitude of VSI and brain amyloid negative scores. As cognitive impairment increased, the mean magnitude of VSI significantly decreased while amyloid probability scores (APS) increased. In fact, individuals with dementia revealed the lowest magnitude of VSI and the highest APS. Our research continues to emphasize the importance of successful multisensory integration in aging, where the establishment of future novel multisensory-based interventions aimed at preventing disability and optimizing independence could prove valuable.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesCognitive DysfunctionVisual PerceptionAgedAged, 80 and overBiomarkersCross-Sectional StudiesFemaleHumansMaleNeuropsychological TestsAmyloid beta-PeptidesBiomarkersamyloid pathologyAPOEbehavioral markersmultisensory integrationsensorimotor processing

Identifiers

PMID40052563
PMCPMC11886890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.